Do you know which doctor should you consult if you have Homocystinuria / Amino Acid metabolism disorder. This and other commonly asked questions about this condition.

The key to finding a cure for homocystinuria—an inherited disease that affects the processing of amino acids within the human body—may lie within Astyanax mexicanus, also known as the Mexican ...

About the Homocystinuria Natural History Study Orphan Technologies is conducting the first-ever prospective natural history study of patients with classical homocystinuria to understand how ...

About the Phase 1/2 Clinical Trial of OT-58 in Homocystinuria The CBS-HCY-CT-01 study is a double-blind, randomized, placebo-controlled, phase 1/2 study to assess the safety, ...

AUSTIN, Texas, June 24, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as ...

Did you know that certain medications can cause symptom of 'Homocystinuria'. Find these drugs listed on the page and be warned of similar symptoms as possible side-effects.

Dublin, Dec. 18, 2024 (GLOBE NEWSWIRE) -- The "Homocystinuria - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This report provides comprehensive ...

Homocystinuria is a disease caused by the deficiency or anomalous function of a protein, with serious consequences such as skeletal deformities, vascular thrombosis and even mental retardation. It ...

Travere Therapeutics has voluntarily paused subject enrolment in the Phase III HARMONY Study of pegtibatinase to treat classical homocystinuria (HCU), a rare genetic metabolic disorder. This ...

Homocystinuria means that the body cannot process the building blocks of amino acids properly. Read on to learn more about high homocysteine levels, including the symptoms, causes, and ...

Travere Therapeutics Announces Positive Topline Results from Cohort 6 in the Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria Travere Therapeutics, Inc. Updated Wed, May 31 ...

Synlogic (NASDAQ: SYBX) has dosed its first healthy volunteer in its Phase 1 study of the investigational oral therapy SYNB1353 for the potential treatment of homocystinuria (HCU).